RETEVMO
Active substance: selpercatinib
TABLET, COATED · SELPERCATINIB 120 mg/1
United StatesActive
Marketing holder: Eli Lilly and Company
Verified 2026-10-09 · openFDA NDC
Analogues in other countries- Source: openFDA NDC
- Countries with the substance registered: 2
Composition
- SELPERCATINIB · 120 mg/1
Analogues by country
Products with the same active substance registered in other countries.
| Country | Products |
|---|---|
| EU 1 |
|
Import and control
Control by country
- United Statesprescription only
Source: openFDA NDC · record 01a12090-cfd7-7720-835f-835973329cd4,01a12092-8bd9-7f6c-8db8-575873f00160,01a12093-7e0e-792a-9bdf-5525a52a65ed,01a12094-dcb2-75a4-8735-578385a4a04a,01a12098-f60e-782c-82ad-d7eeaaf72f82;count=6 · valid from 2026-10-09 · verified 2026-10-09
Registration
- Registration number
- 0002-6120
- Registration status
- Active
- Dispensing
- Prescription only
- Route
- ORAL
Sources
- product · openFDA NDC · 0002-6120 · Verified 2026-10-09 · open in source
- registration_status · openFDA NDC · 0002-6120 · Verified 2026-10-09 · open in source
- ingredients.0 · openFDA NDC · 0002-6120 · Verified 2026-10-09 · open in source